Abstract:The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale international consortia, it is now possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. These studies clearly demonstrate that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription and tissue-specific cellular functions, but its broader consequences include maintaining the integrity of the genome and modulating the immune response. Here, we describe the aberrant DNA methylation changes in human cancers and how they contribute to the disease phenotypes. Aside from CpG island promoter DNA hypermethylation-based gene silencing, human cancers also display gene body DNA hypomethylation that is also associated with downregulated gene expression. In addition, the implementation of whole genome bisulfite sequencing (WGBS) has unveiled DNA hypomethylation of large blocks of the genome, known as partially methylated domains (PMDs), as well as cancer-specific DNA methylation aberrancies at enhancers and super-enhancers. Integrating WGBS and DNA methylation array data with mutation, copy number, and gene expression data has allowed for the identification of novel tumor suppressor genes and candidate driver genes of the disease state. Finally, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets. Mounting evidence shows that DNA methylation data are effective and highly-sensitive disease classifiers, not only from analyses of the primary tumor but also from tumor-derived, cell free DNA (cfDNA) in blood of cancer patients. These findings highlight the power of DNA methylation aberrancies in providing efficacious biomarkers for clinical utility in improving patient diagnostics and their reversal using DNA methylation inhibitors in cancer treatment may be key in surveillance, treatment, and quality of life for cancer patients.

Cytosolic DNA Sensing in Organismal Tumor Control

The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer

DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Cytoplasmic DNA in cancer cells: Several pathways that potentially limit DNase2 and TREX1 activities

Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies

Mechanisms of genomic instability dictate cytosolic DNA composition and dendritic cell mediated anti-tumor immunity

Circulating Methylated DNA As Biomarkers for Cancer Detection

DNA Damage Checkpoint Recovery and Cancer Development

DNA sensing and immune responses in cancer therapy

DNA sensing of dendritic cells in cancer immunotherapy

The Role of DNA Methylation and DNA Methyltransferases in Cancer

At the Crossroads of the cGAS-cGAMP-STING Pathway and the DNA Damage Response: Implications for Cancer Progression and Treatment

DNA Methylation: From Cancer Biology to Clinical Perspectives

DNA Damage and Activation of cGAS/STING Pathway Induce Tumor Microenvironment Remodeling

DNA sensing in cancer: Pro-tumour and anti-tumour functions of cGAS-STING signalling

Metabolic regulation of innate immunity in cancer immunotherapy

Targeting mitotic regulators in cancer as a strategy to enhance immune recognition

Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker

DNA methylation: gene expression regulation

Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses